Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.

Fang-Chun LiuKwing-Chi LukYung-Chih Chen

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2023)

In osteoporotic patients, after 2 years of use, the likelihood of ONJ being induced by denosumab is lower than that of BPs, and the difference increases with time.

Keyphrases

bone mineral density
end stage renal disease
postmenopausal women
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
giant cell
prognostic factors